Search Results

By The ASCO Post Staff  / Quick Chats

Heinz-Josef Lenz, MD, and Axel Grothey, MD, on Liquid Biopsies for Colorectal and Other GI Cancers

By The ASCO Post Staff  / Quick Chats

Heinz-Josef Lenz, MD, and Axel Grothey, MD, on Colorectal Cancer: Molecular Testing and Interpreting an NGS Report

By The ASCO Post Staff  / 2017 ASCO Annual Meeting

Axel Grothey, MD, on Colon Cancer: Results of the IDEA Collaboration

Axel Grothey, MD, of the Mayo Clinic Rochester, discusses study findings on shortening the duration of adjuvant oxaliplatin-based therapy, linked to neurotoxicity, for patients with stage III colon cancer. (Abstract LBA1)

By The ASCO Post Staff  / 2017 ASCO Annual Meeting  / Sunday, June 4, 2017 12:11 PM

ASCO 2017: The IDEA Collaboration: Global Study Sets New Risk-Based Standard to Personalize Chemotherapy for Colon Cancer After Surgery

After surgery for lymph node–positive colon cancer (stage III), some patients may need only half of the long-standing standard course of chemotherapy. In an analysis of 6 clinical trials with over 12,800 patients, 3 months of chemotherapy was nearly as effective as 6 months in patients with...

By Matthew Stenger  / Thursday, May 25, 2017 9:02 AM

Non–V600 BRAF Mutations in Metastatic Colorectal Cancer

As reported by Jones et al in the Journal of Clinical Oncology, BRAF mutations occurring outside of codon 600 are found in a small proportion of cases of metastatic colorectal cancer and are associated with improved clinical outcome. Study Details The retrospective cohort study involved 9,643...

By Axel Grothey, MD  / 2015 NCCN Annual Conference

Axel Grothey, MD, on Optimizing Systemic Therapy Selection in Metastatic Colorectal Cancer

Axel Grothey, MD, of the Mayo Clinic Cancer Center, discusses how the NCCN Guidelines can help oncologists make strategic choices of the various agents available to treat metastatic colorectal cancer, individualizing patient care.

By Eric Van Cutsem, MD, PhD, and Axel Grothey, MD  / 2015 ASCO Annual Meeting

Eric Van Cutsem, MD, PhD, and Axel Grothey, MD, on HERACLES and Other Colorectal Cancer Findings

Eric Van Cutsem, MD, PhD, of University Hospitals Gasthuisberg/Leuven, and Axel Grothey, MD, of the Mayo Clinic, discuss the Italian-led study on trastuzumab and lapatinib in HER2-amplified metastatic colorectal as well as other colorectal cancer findings discussed at ASCO (Abstract 3508).

By Dung T. Le, MD, and Axel Grothey, MD  / 2015 ASCO Annual Meeting

Dung T. Le, MD, and Axel Grothey, MD, on PD-1 Blockade in Tumors With Mismatch Repair Deficiency

Dung T. Le, MD, of Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, and Axel Grothey, MD, of the Mayo Clinic, discuss how mismatch repair status predicts clinical benefit of immune checkpoint blockade with pembrolizumab (Abstract LBA100).

By Chloe Evelyn Atreya, MD, PhD, and Axel Grothey, MD  / 2015 ASCO Annual Meeting

Chloe Evelyn Atreya, MD, PhD, and Axel Grothey, MD, on Efficacy of Targeted Treatments in BRAF-Mutated Metastatic Colorectal Cancer

Chloe Evelyn Atreya, MD, PhD, of the University of California, San Francisco, talks with Axel Grothey, MD, of the Mayo Clinic, about new data on trametinib, dabrafenib, and panitumumab in patients with the BRAF V600E mutation and vemurafenib plus irinotecan and cetuximab in BRAF-mutated metastatic...

By Matthew Stenger  / Friday, December 13, 2013 3:48 PM

No Benefit of Calcium/Magnesium in Preventing Oxaliplatin-Induced Sensory Neurotoxicity in Patients With Colon Cancer

In a phase III N08CB/Alliance trial reported in the Journal of Clinical Oncology, Loprinzi et al assessed whether calcium and magnesium treatment reduced oxaliplatin-related neurotoxicity in patients with colon cancer receiving adjuvant FOLFOX (fluorouracil, leucovorin, and oxaliplatin). They found ...